Login to get immediate access to this content.
LoginSpeaker: Sara Lonardi, Italy
Abstract discussed:
- 2O - Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW - Watch the session from ESMO Gastrointestinal Cancers Congress 2024 now
The speakers and studies featured in this video series were selected independently by ESMO.
Published July 2024